#I DOSER DOSES GRATUITES TRIAL#

At a median follow-up of 45 months (IQR 35вЂ“58), median overall survival was 30 months (95% CI 24вЂ“34) in the twice-daily group versus 25 months (21вЂ“31) in the once-daily group (hazard ratio for death in the once daily group 1в™±8 p=0в™±4). Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms and were lost to follow-up these patients were not included in our analyses. FindingsД«etween April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). The study is registered with ( NCT00433563) and is currently in follow-up. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen. The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. Treatment group assignments were not masked. The allocation method used was minimisation with a random element, stratified by institution, planned number of chemotherapy cycles, and performance status. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1в™µ Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatinвЂ“etoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). Patients were recruited from 73 centres in eight countries. We enrolled adult patients (aged в‰Ґ18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 0вЂ“2, and adequate pulmonary function.

#I DOSER DOSES GRATUITES TRIAL#

The CONVERT trial was an open-label, phase 3, randomised superiority trial.

Advancing women in science, medicine and global health.

The Lancet Regional Health вЂ“ Western Pacific.

The Lancet Gastroenterology & Hepatology.

I doser doses gratuites